Market News & Trends
Oligonucleotides & mRNA Vaccines Dominate in Strategic Alliances for RNA Therapies in Major APAC Countries
RNA-based therapies have already proven and will continue to play an integral role in the development of novel therapeutic agents for diseases in the future.…
CanSinoBIO CSO Shares Latest Results of Innovative Pneumococcal Vaccine
On April 20, the 2024 National Vaccines and Health Conference organized by the Chinese Preventive Medicine Association (CPMA) and the Chinese Center for Disease Control…
Immutep Announces Positive Preliminary Topline Results From TACTI-003 Cohort B
Immutep Limited recently announced preliminary topline results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase 2b trial evaluating eftilagimod alpha (efti) in combination with MSD’s…
PEP-Therapy & Institut Curie Announce First Patients Dosed in Phase 1b Clinical Trial Evaluating PEP-010 in Ovarian & Pancreatic Cancers
PEP-Therapy and Institut Curie recently announced the dosing of the first patients in a Phase 1b clinical trial evaluating PEP-Therapy’s lead candidate, PEP-010, based on…
Mission Bio's New Translocation Analysis Offers Insights Into Critical Safety Assessment for Gene-Edited Cell Products
Mission Bio recently announced the launch of a new single-cell capability that enhances our understanding of translocations (chromosomal rearrangements) in gene-edited therapies. Measuring predicted translocations along…
XOMA Earns $9-Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDA for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
XOMA Corporation recently announced it has earned a $9-million milestone related to the US FDA’s approval of Day One Biopharmaceuticals’ New Drug Application (NDA) for…
Barinthus Bio Announces Topline Data From Phase 1b/2 of VTP-200 in Persistent High-Risk Human Papillomavirus Infections
Barinthus Biotherapeutics plc recently announced topline final data from the APOLLO trial (also known as HPV001), a completed randomized, placebo-controlled Phase 1b/2 dose-ranging trial of…
Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer
Nykode Therapeutics ASA recently announced the initiation of the Phase 2 clinical trial VB-C-04. The trial evaluates VB10.16, the company’s off-the-shelf therapeutic cancer vaccine candidate…
Tiziana Life Sciences Announces Study Results From Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients
Tiziana Life Sciences, Ltd. recently announced a study related to its lead candidate, foralumab, was highlighted in Neurology Today, the official news source of the…
Kynos Therapeutics Announces Positive Top-Line Results From First-in-Human Phase I Study of its KMO Inhibitor
Kynos Therapeutics Ltd recently announced the key findings from the first-in-human Phase 1 trial of its lead drug candidate, KNS366. KMO is an enzyme that…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….